CNS Pharmaceuticals, Inc. (CNSP)
5.75
-0.19
(-3.20%)
USD |
NASDAQ |
Sep 09, 16:00
5.75
0.00 (0.00%)
After-Hours: 18:39
CNS Pharmaceuticals Enterprise Value : -11.30M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | -11.30M |
| September 04, 2026 | -11.61M |
| September 03, 2026 | -11.38M |
| September 02, 2026 | -11.20M |
| September 01, 2026 | -11.37M |
| August 31, 2026 | -11.25M |
| August 28, 2026 | -11.91M |
| August 27, 2026 | -11.92M |
| August 26, 2026 | -12.04M |
| August 25, 2026 | -11.51M |
| August 24, 2026 | -11.30M |
| August 21, 2026 | -11.46M |
| August 20, 2026 | -11.22M |
| August 19, 2026 | -11.46M |
| August 18, 2026 | -11.42M |
| August 17, 2026 | -12.09M |
| August 14, 2026 | -11.92M |
| August 13, 2026 | -12.46M |
| August 12, 2026 | -12.66M |
| August 11, 2026 | -11.95M |
| August 10, 2026 | -12.49M |
| August 07, 2026 | -12.12M |
| August 06, 2026 | -12.33M |
| August 05, 2026 | -12.09M |
| August 04, 2026 | -12.15M |
| Date | Value |
|---|---|
| August 03, 2026 | -11.52M |
| July 31, 2026 | -11.48M |
| July 30, 2026 | -12.90M |
| July 29, 2026 | -12.68M |
| July 28, 2026 | -12.58M |
| July 27, 2026 | -12.58M |
| July 24, 2026 | -12.34M |
| July 23, 2026 | -12.08M |
| July 22, 2026 | -11.51M |
| July 21, 2026 | -12.11M |
| July 20, 2026 | -11.95M |
| July 17, 2026 | -12.62M |
| July 16, 2026 | -13.06M |
| July 15, 2026 | -13.15M |
| July 14, 2026 | -12.88M |
| July 13, 2026 | -12.55M |
| July 10, 2026 | -12.44M |
| July 09, 2026 | -12.21M |
| July 08, 2026 | -12.09M |
| July 07, 2026 | -12.52M |
| July 06, 2026 | -12.71M |
| July 02, 2026 | -12.58M |
| July 01, 2026 | -13.15M |
| June 30, 2026 | -13.00M |
| June 29, 2026 | 0.6488M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.848B |
| Corcept Therapeutics, Inc. | 12.00B |
| Veru, Inc. | 20.88M |
| Johnson & Johnson | 676.38B |
| Eli Lilly & Co. | 1.104T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.588M |
| Total Expenses (Quarterly) | 2.588M |
| EPS Diluted (Quarterly) | -0.3785 |
| Earnings Yield | -410.3% |
| Normalized Earnings Yield | -410.29 |